ChemicalBook > Product Catalog >API >Digestive system drugs >Other digestive system drugs >Gabexate mesylate

Gabexate mesylate

Gabexate mesylate Suppliers list
Company Name: Hangzhou FandaChem Co.,Ltd.
Tel: 008615858145714
Email: fandachem@gmail.com
Products Intro: Product Name:Gabexate mesylate;FOY
CAS:56974-61-9
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Gabexate mesylate
CAS:56974-61-9
Purity:98% Package:1kg;1USD
Company Name: Hubei Jusheng Technology Co.,Ltd.
Tel: 86-18871470254
Email: linda@hubeijusheng.com
Products Intro: Product Name:Gabexate Mesylate
CAS:56974-61-9
Purity:99% Package:5KG;1KG
Company Name: Xiamen AmoyChem Co., Ltd
Tel: +86 592-605 1114
Email: sales@amoychem.com
Products Intro: Product Name:Gabexate Mesylate
CAS:56974-61-9
Company Name: BOC Sciences
Tel: 1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:Gabexate mesylate
CAS:56974-61-9
Remarks:Gabexate is a serine protease inhibitor that inhibits trypsin (IC50= 9.4μM), plasmin (IC50= 30μM), plasma kallikrein (IC50= 41μM) and thrombin (IC50= 110μM). It is used therapeutically (as gabexate me

Lastest Price from Gabexate mesylate manufacturers

  • Gabexate mesylate
  • US $1.00-1.00 / KG
  • 2021-07-20
  • CAS:56974-61-9
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 50tons
  • Gabexate mesylate
  • US $15.00-10.00 / KG
  • 2021-07-13
  • CAS:56974-61-9
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
Gabexate mesylate Basic information
Product Name:Gabexate mesylate
Synonyms:4-[[6-[(Amino-iminomethyl)amino]-1-oxohexyl]oxy]benzoic acid ethyl ester monomethanesulfonate;Gapexate Mesylate;Megacert;Agalit;Arodate;FOY-007;FOY-S 983;Mesyl Gabexate
CAS:56974-61-9
MF:C17H27N3O7S
MW:417.48
EINECS:611-438-2
Product Categories:Aromatics;Inhibitors;Benzoic acid;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Active Pharmaceutical Ingredients
Mol File:56974-61-9.mol
Gabexate mesylate Structure
Gabexate mesylate Chemical Properties
Melting point 89.0 to 93.0 °C
storage temp. Inert atmosphere,Store in freezer, under -20°C
form solid
Merck 14,4320
InChIKeyDNTNDFLIKUKKOC-UHFFFAOYSA-N
CAS DataBase Reference56974-61-9(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
RIDADR 3077
WGK Germany 2
RTECS DG2800800
HS Code 29252900
ToxicityLD50 in mice (mg/kg): 8000 orally; 4700 s.c.; 25 i.v. (Fujita)
MSDS Information
ProviderLanguage
SigmaAldrich English
Gabexate mesylate Usage And Synthesis
Chemical PropertiesGabexate mesylate is supplied as a crystalline solid. A stock solution may be made by dissolving the gabexate (mesylate) in the solvent of choice. Gabexate (mesylate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of gabexate (mesylate) in these solvents is approximately 25 mg/ml.
Gabexate is a competitive inhibitor of serine proteases that inhibits human thrombin, urokinase, plasmin, and Factor Xa (Kis = 0.97, 1.3, 1.6, and 8.5 μM, respectively). It also inhibits bovine thrombin, Factor Xa, and trypsin, and porcine plasma kallikrein (Kis = 1.4, 2.1, 2.6, and 0.2 μM, respectively). In vitro, gabexate inhibits clotting activity of thrombin (IC50 = 10 μM).In vivo, it inhibits fibrin formation in rats when administered at a continuous infusion of 120 μmol/kg per hour. Gabexate inhibits LPS-stimulated TNF-α production from monocytes by inhibiting binding of NF-κB and activator protein 1 (AP-1) to target sites and inducing degradation of IκBα.
OriginatorGabexate Mesylate,Shangai Lansheng
UsesGabexate Mesylate is a serine protease inhibitor. Gabexate Mesylate inhibits trypsin, plasmin, plasma kallikrein and thrombin. Gabexate Mesylate inhibits lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) production through nuclear factor-κB and activator protein-1 activation.
UsesPancreatitis;Serine protease inhibitor.
Gabexate Mesylate is a serine protease inhibitor with IC50 of 0.19 μM which is used therapeutically in the treatment of pancreatitis and disseminated intravascular coagulation.
PreparationGuanidinocaproic acid p-tosyl salt and thionyl chloride were mixed together toreact at the room temperature. An endothermic reaction occurred and thecaproic acid gradually dissolved. Then the reaction mixture was left standingfor 1 to 2 h and was extracted with ether. The lower oily layer and the etherlayer were separated from each other and the lower layer was repeatedlywashed with ether. Then the oily substance (caproic acid chloride) was addedwith benzoic acid ethyl ester in tetrahydrofuran, and the mixture was stirred.After the mixture became a uniform solution, of pyridine were graduallyadded. An exothermic reaction occurred and an oily substance came to beseparated in the lower layer. After the completion of the reaction, the oilysubstance was washed with water and then recrystallized from hot water onceor twice. Thus 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl ester salt wasobtained as white crystals.
To obtained the base 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl esterthe 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl ester salt must be treatedby, for example, sodium hydroxide.
In practice it is usually used as gabexate Mesylate.
Manufacturing ProcessGuanidinocaproic acid p-tosyl salt and thionyl chloride were mixed together to react at the room temperature. An endothermic reaction occurred and the caproic acid gradually dissolved. Then the reaction mixture was left standing for 1 to 2 h and was extracted with ether. The lower oily layer and the ether layer were separated from each other and the lower layer was repeatedly washed with ether. Then the oily substance (caproic acid chloride) was added with benzoic acid ethyl ester in tetrahydrofuran, and the mixture was stirred. After the mixture became a uniform solution, of pyridine were gradually added. An exothermic reaction occurred and an oily substance came to be separated in the lower layer. After the completion of the reaction, the oily substance was washed with water and then recrystallized from hot water once or twice. Thus 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl ester salt was obtained as white crystals.
To obtained the base 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl ester the 4-(6-guanidino-hexanoyloxy)-benzoic acid ethyl ester salt must be treated by, for example, sodium hydroxide.
In practice it is usually used as mesylate.
Therapeutic FunctionEnzyme inhibitor
Mechanism of actionGabexate mesilate (FOY-007) is a protease inhibitor with a broad spectrum inhibiting not only trypsin and kallikrein, but also plasmin, thrombin,factor Xa, elastase, complement 1 (C1), esterase and phospholipase A2. Prophylactic application of FOY-007 or Camostat mesilate (FOY-305) showed some beneficial effect in CDEinduced pancreatitis, cerulein-induced panceratitis and sodium taurocholate-induced panceratitis. The therapeutic effect of FOY-007 in acute panceratitis has been ascribed to its inhibition of pancreatic enzyme activity, like trypsin, thus preventing autodigestion.
Clinical UseGabexate mesylate inhibits proteases and suppresses endothelial cell injury and may be used to treat DIC ascribed to various kinds of diseases.
Therapeutic Function: Enzyme inhibitor
Tag:Gabexate mesylate(56974-61-9) Related Product Information
Ethylparaben Methanesulfonic acid Ethyl benzoate Ethanol Methyl acrylate 6-Aminocaproic acid Guanidineacetic acid GABEXATE GABEXATE MESILATE WS/JP AQUANTRAAL Levofloxacin Methylate BENZOICACID Ethyl 4-hydroxybenzoate,sodium salt Gabexate mesylate Gabexate Doxazosin mesylate Pazufloxacin mesilate Pefloxacin mesylate